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Background: Gaucher disease (GD) type I is the most common type of GD. Its main clinical manifestations are
hepatosplenomegaly as well as bone and hematological abnormalities. The objective of the present study was to
perform a literature review on the growth and metabolism of GD type I patients.
Methods: We searched Pubmed and Scielo.br databases with predetermined study limits: case series (n≥5), clinical
trials, systematic reviews, and meta-analyses, and enzyme replacement therapy (ERT) with alglucerase or
imiglucerase. The outcomes of interest were the following: growth and development, weight, height, malnutrition,
overweight, obesity, basal metabolism, hypermetabolism, insulin resistance, and diabetes. A total of 175 articles
were found, of which 28 met the inclusion criteria; these articles were grouped into three central themes: 1) growth
of children and adolescents before and after ERT; 2) metabolic changes that remained during ERT; and 3) changes
in metabolic status resulting from the treatment.
Results and discussion: The articles included in the present literature review are very heterogeneous, which
hinders the analysis of data. They indicated that GD patients usually show low weight and height before ERT, which
are improved with treatment in children and adolescents. Studies evaluating the energy metabolism by indirect
calorimetry have indicated that the disease is associated with hypermetabolism. In adults, some changes in energy
metabolism remain on ERT, and alterations, such as insulin resistance, seem to be associated with the treatment. It
is not clear which are the required doses of imiglucerase for obtaining an adequate cost-effective relation, as well
as the advisable therapeutic measures to avoid possible long-term adverse effects related to ERT.
Conclusions: ERT tends to normalise the growth of children and adolescents with GD type I, it seems to cause a
partial response in relation to some metabolic changes associated with the disease, and it can causes metabolic
changes such as weight gain in adult patients. Therefore, additional research is necessary.
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Gaucher disease (GD) is an autosomal recessive genetic
disease and one of the most common lysosomal diseases.
GD results from pathogenic mutations of the GBA gene en-
coding the enzyme glucocerebrosidase (acid β-glucosidase),
which is located on chromosome 1q21.31. The absence or
low activity of this enzyme leads to a progressive* Correspondence: idadschwartz@gmail.com
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reproduction in any medium, provided the oraccumulation of its substrate (glucocerebroside) and hence
causes the clinical manifestations of the disease [1].
GD is a pan-ethnic disease and its worldwide preva-
lence is 1 in 50,000-100,000; however, it can be as high
as 1 in 850 in individuals of Ashkenazi heritage [2]. The
most frequent pathogenic mutations in the GBA gene
are p.N370S (c.1226A>G) and p.L444P (c.1448T>C) [3].
The clinical variability found in patients with GD is
related to the type of mutation in the GBA gene and to
the proteins, substrates and metabolism of each individ-
ual, as well as environmental factors; yet, many of these
factors are not completely known.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phenotypic categories: a) type I (OMIM #230800), also
referred to as adult or non-neuronopathic GD, which is
the most common type, characterised by the presence of
visceral (hepatosplenomegaly), bone involvement and
hematologic symptoms (anaemia and thrombocytopenia),
and the absence of significant neurological impairment.
Although it is referred to as adult GD, 66% of patients are
diagnosed before the age of 20 [4]; b) type II (OMIM
#230900), or acute neuronopathic form, has very early
clinical manifestations and significant neurological impair-
ment; c) type III (OMIM #231000), or sub-acute
neuronopathic form, is similar to type II, but less se-
vere. It is estimated that less than 5% of patients with
GD has type II or III GD [5].
For many years, GD was treated with symptomatic
therapies and palliative measures such as splenectomy.
Since the 90s, however, enzyme replacement therapy
(ERT) has been the gold standard treatment. Initially,
ERT with alglucerase was used. Afterwards (1998), the
emergence of ERT with imiglucerase (Genzyme Corpor-
ation, Allston, MA) led to improvements in the quality
of life of GD patients [6]. The response to ERT differs
according to: a) type of GD (type I or III); b) initial
degree of involvement; and c) affected organs. In general,
the best response is obtained in the hematological and
visceral parameters. Some aspects of the bone disease, such
as osteonecrosis, osteofibrosis, and lytic lesions, cannot be
reversed. Nevertheless, early initiation of treatment reduces
the risk of these irreversible complications [2].
The metabolic status of patients with GD type I has
improved with ERT. However, because of its rarity, few
large studies have been performed to specifically assess
the strength of data highlighting the benefits and limita-
tions of ERT in patients diagnosed in childhood and
monitored through adulthood. Therefore, the objective
of the present study was to review the literature about
the nutritional and metabolic status of patients with GD
type I. Our initial hypotheses were: 1) there is high
prevalence of low weight and height in non-treated pa-
tients; 2) ERT has a beneficial effect on these parame-
ters, which is dose-dependent, but may not completely
normalise them; 3) ERT does not fully resolve some of
the metabolic disorders of GD; and 4) ERT may as well
affect other parameters related to energetic metabolism.
Material and methods
All steps of this literature review were performed by one
of the authors of the present article (DD). Inclusion cri-
teria were established based on: a) type of study: case
series (prospective and retrospective, cross-sectional or
longitudinal, controlled or not controlled, only if n≥5),
clinical trials, systematic reviews, and meta-analyses;
b) population: patients with GD type I; c) intervention:ERT with imiglucerase or alglucerase; and d) outcomes:
growth and development, weight, height, malnutrition,
overweight, obesity, basal metabolism, hypermetabolism,
insulin resistance, and diabetes. Studies addressing
specific nutritional deficiencies (e.g. iron, vitamin D, and
B12) were not included in this review.
The electronic search was performed using Pubmed/
Medline and the Scientific Electronic Library Online
(scielo.br). Pubmed/Medline was searched using the fol-
lowing search strategy: Gaucher disease AND (nutrition
OR growth OR anthropometry OR malnutrition OR nu-
tritional status OR REE OR resting energy expenditure
OR calorimetry OR body composition OR insulin resist-
ance OR type II diabetes OR overweight OR obesity OR
calorimetry, indirect OR resting metabolic rate OR energy
metabolism OR indirect calorimetry OR basal metabolic
rate OR basal metabolism OR metabolic status) NOT
Gaucher[Author] Filters activated: Abstract available,
Humans, English, French, Italian, Portuguese, Spanish
and studies published until October 2012. As a result,
165 studies were retrieved. The search in Scielo.br was
performed using the term “Gaucher disease” including
studies published until October 2012; as a result, 10
additional studies were retrieved.
The abstracts of 175 studies were then reviewed, but only
33 met the inclusion criteria and were analysed (142 were
excluded). Based on the review of their bibliographical ref-
erences, two additional studies [7,8] were identified and
included in the present literature review. Thus, 35 articles
were read entirely; seven of them were later excluded:
although they referred to the nutritional parameter studied,
they did not present the specific corresponding data or
analysed data from patients with Gaucher type I and III
jointly. Twenty-eight papers were included in the present
literature review. The description of the search results is
shown in Figure 1.
Results
The 28 studies included in our review were very heteroge-
neous. In addition, most of them included a small sample
and were retrospective and non-controlled (Tables 1 and
2). According to their focus, the selected studies were
grouped considering three aspects of the disease: 1) devel-
opment of children and adolescents during pre- and post-
ERT periods (n=17); 2) abnormalities in energy metabolism
that remained during ERT (n=10); and 3) abnormalities in
metabolic status arising after ERT (n=2, with one of them
[9] also providing data related to the aspect of energy
metabolism).
Growth of children and adolescents in the pre- and post-
ERT periods
The growth of children and adolescents with GD type I has
been monitored by researchers from different countries.
Search strategy
Studies excluded after the reading of 
abstract: 142
1. Type of study: 81
a. Case report (n<5): 25
b. In-vitro studies: 33
c. Non-systematic review: 23
2. Type of disease: 5
a. GD type III: 5
3. Type of treatment: 7
a. Miglustate: 5
b. Velaglucerace alfa 2
4. Type of outcomes: 49
a. No outcome of interest: 49
Studies identified in 
the references: 2
Studies read entirely: 35
(33 of search strategy + 2 reference)
Studies excluded after the reading 




Aimed at the assessment of body 
composition related to bone 
metabolism: 1
Addressed the issue of growth, but 
without nutritional parameters: 2
Data of patients with type I and III 
analyzed together: 4
Studies included in the review: 28
Studies identified: 175
(Pubmed: 165 + Scielo: 10) 
Figure 1 Diagram of the search strategy used in this review (for further details, see section Material and Methods). *did not meet the
inclusion criteria.
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reduced height in children and adolescents with GD type I
before ERT (Table 1) [8,10-22]. Ten of these studies have
compared the basal data with different periods of ERT:
when the same study presented data of different times, we
considered the data of the first evaluation after the
beginning of ERT (Table 1).
One study conducted in South Africa (n=9) analysed
the efficacy of low doses of imiglucerase (±10 UI/kg every
2 weeks): weight and height were assessed at the begin-
ning and at the end of the follow-up period. Results
showed the number of kilograms and centimetres gained
by patients after each year of follow-up: patients grew a
mean of 5.6 cm per year and their weight increased
significantly over time at a mean of 3.9 kg per year [28].
A study including children with GD in Spain (n=19)
associated growth with the levels of insulin-like growth
factor (IGF) before and after ERT. Before ERT, there was
a positive correlation between the standard deviation of
height and that of the IGF-I and IGF binding protein 3
(IGFBP-3). One year after initiating ERT, IGF-I and
IGFBP-3 levels were normalised [29].
Growth and evolution without treatment
Two studies performed in Israel [14,30] assessed growth
and pubertal development in treated and untreated pa-
tients. The first study found that growth deceleration in
untreated patients occurred from 3–5 years old and that
height decreased significantly in later childhood. How-
ever, at the end of the growth period, the difference be-
tween the achieved final height and the target height
was not significant, even considering the presence ofpubertal development delay in 60% of patients, regard-
less of the patient being or not on ERT. Delayed growth
and puberty were more frequent in patients with more
severe disease types [14]. The second study compared
mean and standard deviation of height and weight in
two groups (untreated: n=34; treated: n=29) at baseline
and after three years of follow-up. The mean of z-score
of untreated patients at baseline and at the end of
the follow-up were respectively: height=−0.39; -0.38;
weight=+2.30; +4.83; and the mean of treated patients at
baseline and the end of follow-up were: height=−1.18;
-0.60; weight=−0.84; -0.25. The authors have not speci-
fied the number or percentage of patients with growth
retardation [30].
GD metabolic disorders which remain during ERT
Four studies assessed the basal metabolic rate (BMR) of
GD patients by indirect calorimetry. The first of these
studies was conducted by Barton et al. [31], who
assessed BMR in 25 untreated patients with GD type I
and 92 healthy controls. The BMR of patients and
controls was compared to the predictive equation of
Harris-Benedict. The BMR of controls was 5%, while
that of patients was 44% higher than the BMR predicted
by the equation. The second study was conducted by
Corssmit et al. [23], who assessed BMR in seven un-
treated adult patients with GD type I and seven healthy
controls: patients showed BMR approximately 24%
higher than that of controls. In the third study, Hollak
et al. [24] continued the study conducted by Corssmit,
in which the BMR of the seven patients was reviewed
after 6 months of treatment with alglucerase. By
Table 1 Summary of weight and height in the pre- and post-enzyme replacement therapy (ERT) in children and adolescents with Gaucher disease type I
Before enzyme replacement therapy After enzyme replacement therapy



























Japan Ida et al.
[10]
19 2.7 7.4 10 74 74 - - - -
Canada MacKenzie
et al. [11]
15 - - - - 47 - - - -
ICGGa Kaplan et al.
2006 [12]
496 - - - 34 - - - - -
Tunisia BenTurkia
et al. [13]
11 4.2 8.2 - - 36 - - - -
Albania Shehi et al.
[8]
8 - - - - 25 - - - -
Israel Kauli et al.
[14]
30 - 5.1 - - 63b 11/30 1-7 30 UI/kg/mod -e
Romania Grigorescu
et al. [15]
6 7.9 14.5 - 33 - 6/6 1.5 45 UI/kg/inf -f
Israel Zevin et al.
[16]
30 5.6 9.9 27 33 33 6/30 1 30 UI/kg/mo 50
Italy Bembi et al.
[17]
6 - 10.2 50 50 - 6/6 1.1 43 UI/kg/mo 50
USA Kaplan et al.
[18]
18 4.5 - - 50 50 18/18 1 48 UI/kg/inf 71
ICGGa Kaplan et al.
[18]
81 6.6 - - 48 48 36/81 1.5 - 64
Brazil Oliveira
et al. [19]
13 5.8 - 15c 36c - 13/13 - - 55
Argentina Drelichman
et al. [20]




41 - - - 46c - 41/41 2 35 UI/kg/inf 77
ICGGa Andersson
et al. [22]
702 - - - 42 - 702/702 8 39 UI/kg/inf -g
Yo= years old; ICGG= International Collaborative Gaucher Group.
a- Anderson et al. 2008 included the patients of the study by Kaplan et al. 2006 and 1996.
b- 63% of patients with growth retardation in childhood (19/30).
c- Less than or equal to score 2 standard deviation.
d- The patients received 2.3 U/kg 3 times weekly, i.e., 30 U/kg/month. In children whose bone disease had worsened, the dose was increased to 30 U/kg every 2 weeks.
e- The authors showed the mean of standard deviation score for the height of the group without the individual patients’ data, but noted that the growth velocity gradually increased.
f -The authors reported that the patients normalised their growth, however did not show the corresponding data.





















Table 2 Gaucher disease: summary of the metabolic abnormalities described in treated and untreated patients





7 untreated patients and 7 healthy
controls
Assessing the metabolism of glucose
and fatty acids
After continuous infusion of [3-3H] glucose, basal glucose production was
approximately 30% higher in patients than in controls, while insulin concentration
was also slightly higher in patients. The differences in basal glucose production






7 pre- and post-ERT patients and 7
healthy controls
Evaluating the effect of ERT on the
clinical and metabolic parameters
Continuation of Corssmit’s study and reassessment of parameters after 6 months
of ERT. Increased basal glucose production persisted even with the use of ERT.





26 pre- and post-ERT patients and 26
healthy controls
Comparing serum adiponectin before
and during treatment
GD disease patients showed reduced levels of adiponectin. There was no
correlation between the levels of adiponectin, glucose, and insulin. After ERT, the





6 patients (3 on ERT and 3 untreated)
and 6 healthy controls
Studying the influence of
glycosphingolipids storage in the
metabolism of glucose and fatty acids.
At basal state, the levels of glucosylceramide and ganglioside GM3 in plasma
were higher in patients than in controls. IMGU was lower in patients (n=5) than
in controls. The suppression of lipolysis by insulin was observed to be less





Baseline: 27 patients, 15 pre- and post-
treatment (13 in ERT and 2 in SRT) and
16 control subjects
Determining the levels of
glucosylceramide and ceramide
At basal state, 27 patients were compared with 16 controls and showed
glucosylceramide levels greater than three times that of the controls, while the
ceramide levels were observed to be slightly lower. Regarding the basal state,
patients showed a significant decrease in glucosylceramide levels and a slight
increase in ceramide levels A partial normalization of glucosylceramide levels was
observed over 72 months.
Ghauharali- van




40 treated patients and 30 healthy
controls
Determining ganglioside GM3 in plasma Glucosylceramide and ganglioside GM3 concentrations in plasma were
significantly higher than those observed in the controls. Also, the concentrations
found for splenectomised patients were higher than those of non-
splenectomised patients. In comparison with non-splenectomised patients, the
referred concentrations were higher in splenectomised patients. Plasma
concentrations of ganglioside GM3 have significantly correlated with plasma
chitotriosidase activity, the severity of the disease and hepatomegaly.
Ucar et al.
2009 [9]
Turkey 14 patients undergoing ERT (not
overweight) and 14 healthy controls
Assessing insulin resistance in ERT
patients (not overweight).
One patient had insulin resistance. The difference between the median glucose of
patients (114±5 mg/dL) and that of the post-load controls (103±15.7 mg/dL) was
significant. Insulin levels were significantly higher in patients than in controls.
Triglycerides and fatty acids were also higher in patients with GD. High insulin
levels were positively correlated with free fatty acids, triglycerides, and severity
score.
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the equation of Harris-Benedict in the pre-treatment
period – it was found that they were 29% higher than
the expected and, after 6 months of treatment, it
remained 20% higher. Finally, in a study involving
Brazilian patients, whose mean time of ERT with imiglu-
cerase was 5 years (n=12), it was found that BMR was
27% higher than that of healthy controls [32].
In addition to energy expenditure, other aspects of
metabolism were evaluated by other studies, especially
regarding glucose metabolism and insulin resistance
during pre- and post-treatment periods. A summary of
these studies is shown in Table 2 [7,9,23-27].Abnormalities arising during ERT
A study conducted by Hollak et al. [24] comparing data
from pre- and post-ERT periods and involving seven
adult patients showed that six of them had gained
weight after 6 months of treatment (mean 1.7 kg).
Langeveld et al. [33] reported changes in the metabolic
status of adult patients undergoing ERT. The study in-
cluded the follow-up of 42 patients – 35 of them were
on ERT – and investigated the relationship between
ERT and weight gain, insulin resistance, and type 2 dia-
betes mellitus (type 2 DM). Before ERT, there were 16%
of overweight, the median BMI was 23.3 kg/m2, and no
case of type 2 DM was found. After ERT was initiated,
the median BMI increased to 25.7 kg/m2, the prevalence
rate of type 2 DM went up to 8.2%, and insulin resist-
ance and overweight rates were respectively 6% and 56%.
The untreated patients (n=7) showed initial overweight
rate of 14% and, after 8 years, there was a 57% preva-
lence rate; no cases of insulin resistance or type 2 DM
were reported. A study in Turkey evaluated insulin re-
sistance in ERT patients with GD and without over-
weight (n=14), and showed that they had higher levels of
fasting insulin, post-load glucose and insulin when com-
pared to controls. Elevated insulin levels in GD type I
patients were positively correlated with free fatty acid,
triglyceride, and severity score [9].Discussion
The studies found in the present review were very het-
erogeneous: many analyzed data from patients with GD
type I and III, or children/adolescents and adults jointly,
for instance. It was therefore necessary to reanalyse the
data presented in the original tables focusing only on the
outcomes of interest. In some cases, the studies did not
show complete data regarding treatment, not including
dose, treatment duration, or type of treatment used. In
addition, most of them had small sample size and were
retrospective and cross-sectional studies, what certainly
limited our conclusions.Growth of children and adolescents in the pre- and post-
ERT periods
The results of the studies were presented in a very differ-
ent manner: most did not specifically addressed growth-
related variables (weight and height), mentioning only
one of them (Table 1). Furthermore, several different
units of measure were used to show the results:
percentile [18], z-score [10,13-15,21,22,30], increase in
centimetres or kilograms [28]. Regarding patients' age
(Table 1), some researchers collected this variable during
the diagnostic period and others during the beginning of
the treatment, some used the mean age, whereas others
worked with age groups [12,14,22], and others presented
tables from which data of interest were collected
[11,15-17,20]. Thus, comparisons among the studies
could not be made.
The studies showed that untreated children and ado-
lescents had both weight and height below the expected
rates for their ages. In addition, when there were early
clinical manifestations of the disease, GD was often
more severe and growth rates were even more impaired.
In general, the studies indicated that ERT had a very
positive effect on the growth of children and adoles-
cents, causing a catch-up and a significant improvement
in z-score indexes of weight and height. Yet, it was un-
clear whether the group of patients with GD, as well as
their improved indexes, could fully meet the expecta-
tions of growth based on their genetic heritage. In this
regard, attention should also be devoted to children and
adolescents who apparently have a proper growth level,
given that it may be below the growth expected for their
age when compared to the height of their parents [14,34].
In addition to weight deficit, we also observed that ad-
olescents with GD type I had pubertal development
delay [14]. At first, the treatment led to resumption of
optimal growth levels and adjustment to the different
stages of puberty [34]. It was also suggested that growth
retardation could be related to changes in the IGF axis
of untreated children and adolescents [29]. Considering
the heterogeneity of the disease, it is very important that
researches aimed at a better understanding of the factors
that interfere with the metabolism of patients continue
to be conducted.
The studies did not fully determine the necessary
amount of enzyme for the optimum development of
children and adolescents: some researchers have shown
good results with low doses, whereas others have dem-
onstrated good results with high-dose regimens; how-
ever, they have not clarified the severity score and the
patients’ age at the beginning of the treatment. Since
ERT is an expensive treatment, it is crucial that patients
are monitored by a multidisciplinary team – preferably
in reference centres, for the adequate identification of
the lowest sufficient dose to reverse the current
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it is important to point out that the clinical outcome of
patients found in studies in the past two decades may
have been influenced by other factors besides the treat-
ment with ERT, such as better nutritional intake.
Growth and evolution without treatment
According to studies conducted in Israel [14,16,30], de-
layed pubertal development in patients with untreated
GD did not interfere with their growth target. Therefore,
it seems possible that patients with mild GD may have
adequate development without treatment. In agreement
with the initial hypotheses and according to all the stud-
ies reviewed, we found that: 1) the prevalence of low
weight and height is high in untreated patients from dif-
ferent countries; 2) ERT has beneficial effects on these
parameters; however, it was not possible to determine
whether it can effectively normalise them, since the
studies compared the patients’ growth with the popula-
tion’s growth instead of comparing it with their target of
growth based on their parents' height; such evaluation
was only assessed in the study by Kauli et al. [14];
3) some patients could reach their target growth even
without treatment [14,16,30]; and 4) in relation to the
dose required for adequate development, there seems
not to be a consensus on the fact that higher doses are
more effective in solving growth problems: one study
has found good results with low doses [28], whereas an-
other one has showed that the results are dose-
dependent and more severe patients require a greater
amount of enzyme [18]. Further studies may clarify this
aspect of growth in patients with GD type I.
Metabolic disorders of GD that ERT cannot revert
Studies evaluating the energy metabolism of patients
using indirect calorimetry have suggested that the dis-
ease causes hypermetabolism [23,24,31,32], which would
be responsible for inadequate growth in untreated
children and adolescents. At first, this hypermetabolism
is not observed in other lysosomal diseases with
hepatosplenomegaly [31]. After 6 months of ERT, a
small decrease in energy expenditure was observed in
the seven patients evaluated before and after ERT [24].
However, these patients with BMR 30% higher than the
one estimated by the equation remained with 20% above
the expected. This result is consistent with that found by
Doneda et al. [32], whose patients, continued to have
higher BMR than their controls after 5 years of ERT
with imiglucerase, hence indicating that the treatment
could not normalise the energy expenditure of patients
with GD. Langeveld et al. [35] evaluated whether the
hypermetabolism of patients participating in the re-
search conducted by Corssmit [23] and Hollak [24] was
associated with thyroid disease; no associations werefound between these variables. Despite some hypothesis
on the relation between hypermetabolism and GD, it re-
mains unclear.
Patients with GD showed impaired glucose metabol-
ism [23,24]. In addition, when compared to controls, the
following changes were found in GD patients undergo-
ing ERT: lower plasma adiponectin levels [25], higher
levels of glucosylceramide in patients than in baseline
controls [7,26], partial normalisation of glucosylceramide
levels after 72 months of treatment [7], higher levels of
post-load glucose, insulin, triglycerides, and fatty acids
[9], and greater concentration of ganglioside GM3 in
plasma [26,27]. These changes have indicated that, des-
pite the efficacy of the treatment in solving some mani-
festations of the disease, it has not been as effective in
treating certain metabolic changes. The hypothesis pro-
posed in the present review that ERT shows limitations
in solving some GD metabolic problems seems to be
corroborated by the studies analysed; therefore, further
studies and longer follow-up periods may contribute to
better understanding both the mechanism of the disease
and its evolution.
Abnormalities associated with ERT: overweight, insulin
resistance, and type 2 DM
A study conducted by Langeveld et al. [33] in the
Netherlands, with a cohort of 49 patients, identified a
higher percentage of patients with type 2 DM and over-
weight after some years of ERT. The development of
type 2 DM may be related to the several changes found
in the glucose metabolism of patients with GD.
The prevalence of overweight was not different from
that observed in studies involving the general popula-
tion; yet, overweight onset was quite different: GD pa-
tients started presenting lower levels of weight when
ERT was initiated (even considering organomegalies).
Hence, weight gain was more significant than in the
general population. According to the author, one of the
reasons for this finding was that ERT reduced the
hypermetabolism of GD, but without the proportional
adjustment of energy intake by patients, thus resulting
in a higher level of weight gain. Regarding children and
adolescents, this caloric difference would be directed to
growth and would explain why they have not shown
the same trend of overweight observed in adults
undergoing ERT.
According to a study conducted by Ucar et al. [9], it is
possible that patients with more severe GD have a re-
duction in insulin sensibility and a greater tendency to
develop type 2 DM, even without being overweight.
Additional studies with larger numbers of patients and
other populations are needed to verify this hypothesis.
Another consideration relates to differences in param-
eters due to age at the beginning of treatment: it is
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who started ERT in an older age are different from those
who started treatment at an early age. There is no con-
sensus about the dose required to achieve a cost-
effective adequate and therapeutic measures advisable to
avoid possible long-term adverse effects, such as weight
gain and insulin resistance, as described in some studies.
Currently, this information is even more relevant as new
enzymes have been approved, and it is important that
doctors and patients have consistent information about
each of them in order to choose the best treatment.
Conclusions
Most studies have not specifically addressed growth and
metabolism and GD. Nevertheless, several studies have
dealt with this topic, especially regarding the growth re-
tardation rate of children and adolescents and the de-
layed puberty in untreated adolescents. Although some
changes in metabolism remained, ERT contributed to
normalise the development of children and adolescents.
Studies have also shown that some patients with milder
disease may have adequate growth without treatment.
As for adults, ERT seemingly causes weight gain, insulin
resistance, and development of type 2 DM.
According to the available literature, it is not possible
to determine if hypermetabolism is a characteristic of
GD, if it is caused by factors also found in other chronic
diseases, or even if it correlates with the severity of the
clinical manifestations of patients, which has an impact
on the establishment of the prognosis or management.
We believe that further studies, especially controlled and
longitudinal studies including an adequate sample size,
are needed to address these gaps in knowledge.
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